Targeting of HDAC8 and investigational inhibitors in neuroblastoma

Biomarkers for predicting clinical responses to HDAC inhibitors

(2009) Lindsay Stimson et al.   CANCER LETTERS

Histone deacetylase inhibitors as anti-neoplastic agents

(2009) Nicolas Batty et al.   CANCER LETTERS

HDACi – Targets beyond chromatin

(2009) Marc Buchwald et al.   CANCER LETTERS

Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications

(2009) D. S. Schrump   CLINICAL CANCER RESEARCH

Targeting Histone Deacetylases in Neuroblastoma

(2009) O. Witt et al.   CURRENT PHARMACEUTICAL DESIGN

Epigenetic control of skull morphogenesis by histone deacetylase 8

(2009) M. Haberland et al.   GENES & DEVELOPMENT

Histone deacetylase inhibitors: Potential in cancer therapy

(2009) P.A. Marks et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells

(2008) Dennis Wegener et al.   ANTI-CANCER DRUGS

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

(2008) Nagma Khan et al.   BIOCHEMICAL JOURNAL

Structural Studies of Human Histone Deacetylase 8 and Its Site-Specific Variants Complexed with Substrate and Inhibitors†,‡

(2008) Daniel P. Dowling et al.   BIOCHEMISTRY

Anti-neuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro

(2008) Hedwig E. Deubzer et al.   CANCER LETTERS

HDAC family: What are the cancer relevant targets?

(2008) Olaf Witt et al.   CANCER LETTERS

Acetylation Is Indispensable for p53 Activation

(2008) Yi Tang et al.   CELL

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

(2008) L. Gore et al.   CLINICAL CANCER RESEARCH

Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin

(2008) D. S. Schrump et al.   CLINICAL CANCER RESEARCH

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors

(2008) N. L. Steele et al.   CLINICAL CANCER RESEARCH

Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes

(2008) V. M. Klimek et al.   CLINICAL CANCER RESEARCH

Histone Deacetylase 8 in Neuroblastoma Tumorigenesis

(2008) I. Oehme et al.   CLINICAL CANCER RESEARCH

Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks

(2008) Sarah K Knutson et al.   EMBO JOURNAL

Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice

(2008) Rusty L. Montgomery et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors

(2008) Lillian L. Siu et al.   JOURNAL OF CLINICAL ONCOLOGY

A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas

(2008) S Balasubramanian et al.   LEUKEMIA

Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells

(2008) Annick Muhlethaler-Mottet et al.   Molecular Cancer

Deletion of Histone Deacetylase 3 Reveals Critical Roles in S Phase Progression and DNA Damage Control

(2008) Srividya Bhaskara et al.   MOLECULAR CELL

The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men

(2008) Xiang-Jiao Yang et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation

(2008) R. B. Parmigiani et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells

(2007) F Condorelli et al.   BRITISH JOURNAL OF PHARMACOLOGY